Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Liver Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
13 drugs · 38 active trials
14 drugs · 333 active trials
Outside the funnel: Phase not stated 3. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 10 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Fludarabine | Phase 2 | Phase 2 | 9 | 6 | 0 | 30 | 0 | — | — | 1999-11 |
| Paclitaxel | Phase 2 | Phase 2 | 3 | 1 | 0 | 8 | 0 | — | — | 2007-11 |
| Palbociclib | Phase 2 | Phase 2 | 3 | 1 | 0 | 6 | 0 | — | — | May 25, 2011 |
| Erdafitinib | Phase 2 | Phase 2 | 3 | 0 | 0 | 3 | 0 | — | — | Aug 17, 2015 |
| Larotrectinib | Phase 2 | Phase 2 | 3 | 0 | 0 | 3 | 0 | — | — | Aug 17, 2015 |
| Temozolomide | Phase 2 | Phase 2 | 2 | 1 | 0 | 7 | 0 | — | — | 2000-06 |
| Pemigatinib | Phase 2 | Phase 2 | 2 | 2 | 0 | 4 | 0 | — | — | Nov 11, 2022 |
| Sapanisertib | Phase 2 | Phase 2 | 2 | 1 | 0 | 4 | 0 | — | — | Jun 18, 2014 |
| Pralatrexate | Phase 2 | Phase 2 | 2 | 0 | 0 | 3 | 0 | — | — | Jul 6, 2011 |
| Binimetinib | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Ensartinib | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Jul 31, 2017 |
| Immunotherapy | Phase 2 | Phase 2 | 2 | 1 | 0 | 2 | 0 | — | — | Jul 25, 2025 |
| Ivosidenib | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Jul 31, 2017 |
| Selpercatinib | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Jul 31, 2017 |
| Tipifarnib | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Jul 31, 2017 |
| Leucovorin | Phase 2 | Phase 2 | 1 | 0 | 0 | 13 | 0 | — | — | 1998-08 |
| Lenalidomide | Phase 2 | Phase 2 | 1 | 1 | 0 | 11 | 0 | — | — | 2009-01 |
| Rituximab | Phase 2 | Phase 2 | 1 | 0 | 0 | 5 | 0 | — | — | 2003-08 |
| Dasatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | 2007-04 |
| Docetaxel | Phase 2 | Phase 2 | 1 | 1 | 0 | 4 | 0 | — | — | 2001-09 |
| Bendamustine | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | 2011-07 |
| Brentuximab Vedotin | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Mar 5, 2013 |
| Hydroxychloroquine | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | Feb 16, 2017 |
| Sonidegib | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | 2011-02 |
| Tazemetostat | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Jul 31, 2017 |
| Trametinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | 2014-02 |
| Belinostat | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 2006-05 |
| Cobimetinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Feb 8, 2018 |
| Copanlisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Cytarabine | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 2015-02 |
| Derazantinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Sep 28, 2017 |
| Fruquintinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Nov 23, 2021 |
| Gefitinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 2004-02 |
| Guadecitabine | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 2012-12 |
| Ipilimumab/Nivolumab Regimen | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Feb 12, 2019 |
| Olaparib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Jul 31, 2017 |
| Sacituzumab Govitecan | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Dec 17, 2012 |
| Samotolisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Jul 31, 2017 |
| Selumetinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 2007-11 |
| Trastuzumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Vemurafenib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Jul 31, 2017 |
| Acalabrutinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Dec 13, 2019 |
| Adavosertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Afatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Capivasertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Cemiplimab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Jul 23, 2019 |
| Crizotinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Dabrafenib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Denosumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | May 1, 2026 |
| Dostarlimab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Mar 6, 2025 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.